Cue Biopharma licenses Ascendant-221 anti-IgE antibody from Ascendant Health Sciences
PUBT · 8h ago
Share
Listen to the news
- Cue Biopharma entered an exclusive license deal with Ascendant Health Sciences to develop, manufacture, commercialize Ascendant-221, a Phase 2 anti-IgE antibody for allergic diseases.
- Cue received global rights excluding mainland China, Hong Kong, Macau, Taiwan.
- Agreement includes USD 15 million upfront payment.
- Ascendant eligible for up to USD 676.5 million in development, regulatory, commercial milestones.
- Cue targets global Phase 2b food allergy trial following Phase 2 chronic spontaneous urticaria readout expected in 2H 2026 from Ascendant Health-led China study.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cue Biopharma Inc. published the original content used to generate this news brief on April 30, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved